We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Microfluidic Device for Cancer Detection Precisely Separates Tumor Entities

By LabMedica International staff writers
Posted on 15 Apr 2024
Print article
Image: The device can serve as a sample pretreatment tool for cytological diagnosis of malignant effusions (Photo courtesy of Microsystems & Nanoengineering: Zhu, Z., Ren, H., Wu, D. et al.)
Image: The device can serve as a sample pretreatment tool for cytological diagnosis of malignant effusions (Photo courtesy of Microsystems & Nanoengineering: Zhu, Z., Ren, H., Wu, D. et al.)

Tumor cell clusters are increasingly recognized as crucial in cancer pathophysiology, with growing evidence of their increased resistance to treatment and higher metastatic potential compared to single tumor cells. However, traditional cell separation techniques, which typically focus on isolating single tumor cells, are inadequate for simultaneously purifying tumor cell clusters. In response, researchers have developed a microfluidic method capable of high-throughput, continuous-flow ternary separation of single tumor cells, tumor cell clusters, and white blood cells (WBCs) from clinical samples of pleural or abdominal effusions. This technique incorporates slanted spiral channels and periodic contraction-expansion arrays to achieve separation.

The novel spiral-contraction-expansion device developed by researchers from Southeast University (Nanjing, China) utilizes slanted spiral channels combined with periodic contraction-expansion arrays for high-throughput, continuous-flow ternary separation of tumor cells and tumor cell clusters from a background of blood cells. By introducing periodic contraction-expansion arrays, the spiral-contraction-expansion device allows for the size-based ternary separation of cells under the combined action of the inertial lift force, Dean drag force, and local vortex-induced lift force. The researchers first characterized the ternary inertial focusing of differently sized particles in their spiral-contraction-expansion device and optimized the operational flow rate.

Subsequent evaluation was conducted of the device’s separation performance, recovery ratio, and purity of the tumor cells and clusters. The researchers also examined the device’s ability to carry out ternary separation of exfoliated tumor cells, tumor cell clusters, and WBCs from clinical pleural or abdominal effusions derived from cancer patients. The spiral-contraction-expansion device provides numerous benefits, including label-free, continuous-flow, high-throughput separation of tumor cells and clusters from cancer patient effusions in a single step. This method offers significant potential for enhancing the diagnosis and monitoring of treatment in cancer patients by analyzing malignant effusions with higher precision and efficiency.

Related Links:
Southeast University

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Creatine Kinase-MB Assay
CK-MB Test
New
Ultra-Low Temperature Freezer
iUF118-GX

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.